Navigation Links
Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
Date:8/19/2007

Levodopa Remains the Most Widely Prescribed Drug for Parkinson's Disease,

According to a New Report from Decision Resources

WALTHAM, Mass., Aug. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that 61 percent of newly diagnosed Parkinson's disease patients do not receive any drug treatment in the first year of diagnosis. According to the new report entitled Treatment Algorithms for Parkinson's Disease, failure of newly diagnosed Parkinson's disease patients to receive pharmacological treatment within the first 12 months of diagnosis likely occurs as a result of patients' decisions to delay treatment until symptoms become sufficiently troublesome. Furthermore, because the guidelines of the American Academy of Neurology (AAN) do not define specific time periods for when treatment should be initiated, patients may be reluctant to begin levodopa therapy, such as with Bristol Myers Squibb's Sinemet, knowing that side-effects will arise, specifically motor response complications.

Levodopa provides greater motor benefit than dopamine agonists, such as GlaxoSmithKline's Requip or Boehringer Ingelheim's Mirapex, but inevitably results in the development of levopoda-induced side effects, including dyskinesias, off time (sudden motor switches between normal and Parkinson movements) and wearing-off complications (shortened periods of benefit after each levodopa use).

"Levodopa continues to be the gold-standard Parkinson's disease treatment, with 99% of neurologists and 95% of PCPs we surveyed currently prescribing it in their Parkinson's disease practice," said Nicole Westphal, Ph.D., analyst at Decision Resources. "However, first-line levodopa use will decrease over the next two years as physicians increasingly use levodopa-sparing approaches. Patient demand for well-tolerated, levodopa-sparing treatments will continue to drive increases i
'/>"/>

SOURCE Decision Resources

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer
6. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
7. Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate Dependency Treatment Are Mothers
8. Eighty-one Percent of U.S. Adults say that Birth Control Pills and Procedures Should Be Covered by Health Insurance
9. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
10. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
11. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , Apr. 17, 2015 Steven Rash ... ALGA ), and its operating subsidiary American Seed & ... exclusive presentation to investors yesterday in New York City.  ... The American Seed & Oil Company has ... Hippie Butter Hemp Seed Foods , the ...
(Date:4/17/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kh5kqg/the_corporate ) ... Corporate Reputation of Pharma - The Patient Perspective ... to their offering. The Corporate Reputation ... its fourth edition. This report contains the latest ... annual Corporate Reputation report, the author surveys a ...
(Date:4/17/2015)... TWi Pharmaceuticals, Inc. ("TWi", Stock Ticker:4180.TT) today announced that ... , has obtained state sales licenses from all 50 ... close contact with the major nationwide retail pharmacy distributors ... specialty generic products sold through these nationwide pharmacy distribution ... According to IMS Health, the U.S. pharma market is ...
Breaking Medicine Technology:American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2
... LAKE GENEVA, Wis., Jan. 4, 2012 "My philosophy in ... so they can fully achieve their goals," mentions Robert ... Walworth Hospital and Medical Center in Lake Geneva, Wisconsin ... Dr. Paresi recently joined Mercy Health System with the ...
... PHOENIX, Jan. 4, 2012   Kedem Pharmaceuticals Inc. ... sublingual drug delivery is pleased to announce that it ... compliant formulation development company, Corealis Pharma, Inc. for the ... the Company,s second lead therapeutic drug. The KDM-1102 drug ...
Cached Medicine Technology:Fulfill New Year Resolutions with Cosmetic Surgery 2Kedem Pharmaceuticals Engages a FDA Compliant Contract Formulation Development Company for the Production of KDM-1102 Clinical Materials 2Kedem Pharmaceuticals Engages a FDA Compliant Contract Formulation Development Company for the Production of KDM-1102 Clinical Materials 3
(Date:4/18/2015)... York (PRWEB) April 18, 2015 Thousand ... filed on behalf of individuals who were allegedly harmed ... continue to move forward in the U.S. District Court, ... April 10th, the Court has amended an earlier Case ... cases. Among other things, the new amendment permits the ...
(Date:4/18/2015)... More than 2000 styles of newly designed prom dresses ... store carrying celebrity inspired special occasion dresses. With the ... dresses for their prom. For those who are still ... would be an ideal choice. , "We have ... by the most loved styles seen at this years ...
(Date:4/18/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Therapy Association Annual Conference to be held May ... SC. , The SCAPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
(Date:4/18/2015)... 2015 PHOENIX, ARIZONA – In March, ... 11 other secure destruction professionals across the United States, ... He will now display “CSDS” as a professional title ... the National Association of Information Destruction 2015 Annual Conference ... Texas. Of the 20 people who took the exam, ...
(Date:4/17/2015)... Heritage Woods of McLeansboro, a Gardant affordable ... Celebration on April 20 with a day full of ... and soul. , The community, which is located at ... of all incomes, including those on Medicaid, who need ... Week is observed every April and highlights the communities ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3
... Board: HFIT), a leading provider of integrated,employee health and ... the B. Riley & Co. 9th Annual Las Vegas ... The Health Fitness,presentation is scheduled to begin at 10 ... the presentation will be Gregg Lehman, Ph.D.,president and chief ...
... ,Proud to be GI Awards, Honored for Commitment to Patient ... ... Today, Procter and Gamble,Pharmaceuticals (P&G) is encouraging GI and Endoscopy professionals ... through its support of the Society of Gastroenterology,Nurses and Associates, Inc. (SGNA) ...
... Malaria Therapy, written by WRAIR researchers Dr. Qugui Li, Dr. ... of Experimental Therapeutics at the WRAIR, Silver Spring, MD) provides ... in the treatment of one of the oldest and still ... , WRAIR, initially known as the Army Medical School, was ...
... Reports Record 2007 Revenue of $4.9 Million, an Increase of 126% ... -, - Removal ... ... Today at 4:15 p.m. ET -, DENVER, March 26 XELR8 Holdings, Inc. (Amex:,BZI), a ...
... 23 percent for moisture-barrier film, PHILADELPHIA, March 26 ... will expand production of Aclar(R) film to meet growing,demand ... pharmaceutical packaging., An upgrade of existing production capability, ... production by up to,23 percent by end of 2008 ...
... For decades, the American,Academy of Dermatology has advised ... cancer -- and that same advice holds true today,despite ... benefits of vitamin D are well known, it also ... cause skin cancer,",stated dermatologist C. William Hanke, MD, FAAD, ...
Cached Medicine News:Health News:Health Fitness to Present at B. Riley & Co. 9th Annual Las Vegas Investor Conference 2Health News:Nationwide Awards Recognize Nurses, Associates and Nursing Teams That Specialize in Gastroenterology and Endoscopy 2Health News:Nationwide Awards Recognize Nurses, Associates and Nursing Teams That Specialize in Gastroenterology and Endoscopy 3Health News:WRAIR investigators pioneering work on an exciting new class of antimalarial compounds 2Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 2Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 3Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 4Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 5Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 6Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 7Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 8Health News:Honeywell Expands Aclar(R) Production for Pharmaceutical Industry 2Health News:Honeywell Expands Aclar(R) Production for Pharmaceutical Industry 3Health News:American Academy of Dermatology Issues Statement Urging the Public to be Sun Smart(SM) 2
...
...
...
Solid blade speculum designed for both temporal and superior approach ocular surgery. Adjustable with thumb screw. Manufactured in titanium....
Medicine Products: